Stocks
Tenax Therapeutics, Inc.TENX
NASDAQHealthcareBiotechnology$1.72
Price as of · delayed, not real-time
A clinical-stage biopharmaceutical company developing oral and inhaled therapies for pulmonary hypertension and heart failure. Its lead candidate, TNX-201, is an oral imatinib formulation in Phase 3 trials for pulmonary arterial hypertension, with additional pipeline assets targeting preserved ejection fraction heart failure. Investors track the stock for its late-stage cardiovascular programs and potential regulatory milestones.
52W Range: $1.31-$19.40
Congressional Interest in Tenax Therapeutics, Inc. (TENX)
No congressional trades have been disclosed for Tenax Therapeutics, Inc. (TENX) yet. All data is sourced from STOCK Act periodic transaction reports filed with Congress.
Total Disclosures
0
Unique Politicians
0
Buys
0
Sells
0
Who in Congress Is Trading TENX?
No congressional trades found for this stock.